Characterisation of the rat and mouse homologues of gC1qBP, a 33 kDa glycoprotein that binds to the globular `heads' of C1q  by Lynch, Nicholas J et al.
FEBS 19503 FEBS Letters 418 (1997) 111-114 
Characterisation of the rat and mouse homologues of gClqBP, a 33 kDa 
glycoprotein that binds to the globular 'heads' of Clq 
Nicholas J. Lyncha'b, Kenneth B.M. Reidc, Rocco H. van den Bergc, Mohamed R. Dahac, 
Leonora A.E. Leighc, Berhane Ghebrehiwetf, Wallace B.L. Limd, Wilhelm J. Schwaeblea'b'* 
0Department of Microbiology and Immunology, University of Leicester, University Road, Leicester LEI 9HN, UK 
bInstitute of Anatomy and Cell Biology, University of Marburg, Marburg, Germany 
CM.R.C. Immunochemistry Unit, Department of Biochemistry, University of Oxford, Oxford, UK 
dDepartment of Zoology, University of Hong Kong, Hong Kong, China 
''Department of Nephrology, University Hospital Leiden, Leiden, The Netherlands 
'Department of Medicine, State University of New York, New York, NY, USA 
Received 15 October 1997 
Abstract gClqBP is a 33 kDa glycoprotein that binds to the 
globular 'heads' of Clq. We have cloned cDNAs encoding the rat 
and mouse homologues of gClqBP. Comparison of the cDNA-
derived amino acid sequences of gClqBP reveals that either of 
the rodent sequences is 89.9% identical to the reported human 
sequence. Recombinant rat gClqBP binds avidly to human Clq. 
gClqBP mRNA is abundantly expressed in every rat and mouse 
tissue analysed. Rat mesangial cells synthesise gClqBP, but do 
not express gClqBP on the cell surface. In rat serum, gClqBP is 
present at low levels. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
C l q is the recognition subunit of the first component of 
complement. In addition to its role in the activation of the 
classical pathway, C l q elicits various receptor-mediated bio-
logical functions such as enhancing phagocytosis [1,2], neutro-
phil superoxide production [3], Ig synthesis [4,5], chemotaxis 
[6], cell adhesion [7], and the regulation of platelet function 
[8]. All types of peripheral blood cells, except erythrocytes, 
bind C l q [9]. C l q binding sites have also been found on 
endothelial cells [10], fibroblasts [11,12], smooth muscle cells, 
and epithelial cells [13]. Several binding molecules and poten-
tial receptors for C l q have been described: a cell surface 
receptor of 60 k D a isolated from tonsil lymphocytes [14]; a 
cell surface receptor of 100 k D a isolated from U937 cells [15]; 
and a glycoprotein of 33 k D a that binds to the globular 
'heads ' of C l q [16]. The 60 k D a C l q receptor (termed 
c C l q R or collectin receptor) binds to the collagenous region 
of C l q and to the collagenous region of the collectin proteins 
lung surfactant protein A (SP-A), mannose binding lectin 
(MBL), CL43, and conglutinin [17,18]. Also the 100 k D a 
monocyte C l q receptor binds to the collagenous region of 
C l q and the collectins MBL and SP-A [19,20]. Characterisa-
tion of c C l q R by peptide sequence analysis [21] revealed that 
c C l q R is a membrane-associated form of calreticulin (CaR), a 
highly conserved abundant calcium-binding protein [22]. Fur-
ther evidence for the identity of c C l q R with CaR was pro-
vided by the localisation of a C l q binding site in CaR [23]. A 
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c D N A sequence has been reported for the monocyte C l q 
receptor of 100 k D a indicating that this molecule is a novel 
protein furnished with a t ransmembrane anchor [24]. 
A 33 k D a glycoprotein (gClqBP or g C l q R ) which binds 
specifically, and with high affinity, to the globular 'heads' of 
C l q was first reported by Ghebrehiwet et al. [16]. Recombi-
nant g C l q B P was shown to inhibit complement activation in 
human serum. g C l q B P also binds to the heparin binding, 
multimeric form of vitronectin and the ternary vitronectin-
thrombin-anti thrombin III, but not to the monomeric, un-
complexed form of vitronectin in plasma [25]. Moreover, 
g C l q B P was shown to bind to H-kininogen and to factor 
XII [26,27]. g C l q B P is identical to a HeLa cell protein (p32 
or SF2) discovered by Krainer et al [28,29] and initially 
thought to be a p re -mRNA splicing factor. However, subse-
quent work by the same group casts serious doubt on this 
theory [30]. Here we report the primary structure of the rat 
and mouse homologues of gClqBP , their m R N A expression, 
their cellular localisation, and C l q binding activity. 
2. Materials and methods 
2.1. cDNA cloning and sequencing 
Proprietary ^.ZAPII rat macrophage, ^.ZAPII rat liver, ^.ZAPII rat 
brain cortex and ^.ZAP mouse liver cDNA libraries were purchased 
from Stratagene, Cambridge, UK. Isolated XZAP clones were con-
verted into pBluescript SK~ plasmid clones by in vivo excision, fol-
lowing the supplier's protocol. Sequencing of both strands was carried 
out by the dideoxynucleotide chain termination procedure using 
[a-35S]dATP and the T7 Sequencing reagent kit (Pharmacia, Uppsala, 
Sweden). 
2.2. Ribonucleic acid extraction and Northern blot analysis 
Total RNA was isolated by the method of Chirgwin et al. [31]. 15 
jig of total RNA, or 2 (ig of poly(A)~ RNA, was separated on form-
aldehyde-containing 1.2% agarose gels. Northern blot analyses were 
carried out following standard methods [32]. The cDNA insert of 
clone RB7.12 was labeled with [cx-32P]dCTP using the random prim-
ing method [32]. To validate Northern blot results, the filters were 
rehybridised with a a-32P-labeled fi-actin cDNA probe [33]. 
2.3. Prokaryotic expression of recombinant rat gClqBP 
Recombinant rat gClqBP was expressed as a thioredoxin fusion 
protein in Escherichia coli using plasmid pTrxfus (Invitrogen BV, 
Leek, The Netherlands). Clone RB7.12 was used as a template for 
PCR using primer RGXbal (5'-GTCTAGACCCCGCGATGCTCCC-
TCTG-3') with an Xbal site arranged to allow in-frame cloning into 
pTrxfus and primer BSSV/I (5'-GGATCGCCCGGGCTGCAGG-3', a 
pBluescript primer modified to include a Srfl site). The PCR product 
was digested with SrfilXbal and subcloned into pTrxfus. Expression 
was performed according to the manufacturer's protocol. The fusion 
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protein was affinity purified by binding to Thiobond resin (Invitro-
gen). 
2.4. Antibodies 
An NZW rabbit was injected s.c. with 100 u.g of recombinant rat 
gClqBP thiofusion protein in 500 ul of PBS plus 1 volume incomplete 
Freund's adjuvant. Three further immunisations were done at fort-
nightly intervals before the rabbit was bled. Anti-human gClqBP 
polyclonal antibodies were prepared as described in [16]. 
2.5. Solid phase binding assay 
An ELISA was devised to determine the binding of biotinylated rat 
gClqBP thiofusion protein to Clq. Proteins were biotinylated accord-
ing to established methods [35]. Wells of a Nunc PolySorp microtitre 
plate (Gibco-BRL Life Technologies) were coated with increasing 
concentrations of human Clq in 15 mM Na 2C0 3 , 35 mM NaHC0 3 
pH 9.6 and incubated for 2 h at RT. After coating, the plate was 
washed three times with 20 mM Tris-Cl, 150 mM NaCl, 0.05% Tween 
20, 1 mg/ml BSA, blocked for 2 h at RT with 300 ill/well of the same 
buffer and washed again. 100 ul of a 1 ug/ml solution of either bio-
tinylated rat gClqBP thiofusion protein or, for controls, biotinylated 
thioredoxin peptide, was added to each well and incubated for 2 h at 
RT. The plate was washed three times and developed with ExtraAvi-
din alkaline phosphatase followed by the chromogenic substrate Sig-
ma 104 pNPP (Sigma-Aldrich Company, Poole, UK). Absorbance 
was measured at 405 nm. 
2.6. Cells and FACS analysis 
Rat mesangial cells (RMC) were isolated and maintained as previ-
ously described [36]. Cultured, adherent RMC were detached using 20 
mM EDTA/PBS, incubated for 30 min in PBS, 1% BSA and 1% 
normal rat serum at 4°C and washed. Cells were exposed for 1 h at 
4°C to either 1/500 diluted polyclonal rabbit anti-rat gClqBP or, for 
controls, 1/500 diluted pre-immune serum. Cells were washed, incu-
bated for 1 h at 4°C with FITC conjugated goat anti-rabbit IgG and 
analysed using a FACScan (Becton Dickinson, Cowley, UK). Intra-
cellular gClqBP was assayed as above, except that cells were permea-
bilised with PBS containing 1% (v/v) saponin (Sigma-Aldrich) for 45 
min at RT and washed, prior to incubation with the primary anti-
body. 
3. Results 
Human gClqBP cDNA [16] was labeled with [cc-32P]dCTP 
and used to screen rat macrophage and liver cDNA libraries. 
Positive plaques were picked and the pBluescript SK~ plasmid 
rescued from the A.ZAPII phagemid vector by in vivo excision. 
Rat KLPLLRCVPR ALGAAATGLR ASIPAPPLRH LLQPAPRPCL RPFGLLSVRA -21 
Kouse MLPLLRCVPR SLGAAS.GLR TAIPAQPLRH LLQPAPRPCL RPFGLLSVRA -22 
Human MLPLLRCVPR VLGSSVAGLR AAAPASPFRQ LLQPAPRLCT RPFGLLSVRA -24 
Rat GSARRSGLLQ PPGSCA..CA .AALHTEGDK AFVEFLTDEI KEEKKIQKHK 27 
Mouse GSARRSGLLQ PPVPCA..CG CGALHTEGDK AFVEFLTDEI KEEKKIQKHK 27 
Human GSERRPGLLR PRGPCACGCG CGSLHTDGDK AFVDFLSDEI KEERKIQKHK 27 
Rat SLPKMSGDGE LEVNGTEAKL LRKVAGEKIT VTFNINNSIP PTFDGEEEPS 
House SLPKMSGDWE LEVNGTEAKL LRKVAGEKIT VTFNINWSIP PTFDGEEEPS 
Human TLPKMSGGWE LELNGTEAKL VRKVAGEKIT VTFNINNSIP PTFDGEEEPS 
Rat QGQKAEEQEP ELTSTPNFW EVTK.TDGKK TLVLDCHYPE DEIGHQDEAE 126 
Mouse QGQKAEEQEP ERTSTPNFW EVTK.TDGKK TLVLDCHYPE DEIGHEDEAE 126 
Human QGQKVEEQEP ELTSTPNFW EVIKNDDGKK ALVLDCHYPE DEVGQEDEAE 127 
Rat SDIFSIKEVS FQTTGDSEWR DTNYTLNTDS LDWALYDHLM DFLADRGVDN 176 
Mouse SDIFSIKEVS FQATGDSEWR DTNYTLNTDS LDWALYDHLM DFLADRGVDN 176 
Human SDIFSIREVS FQSTGESEWK DTNYTLNTDS LDWALYDHLM DFLADRGVDN 177 
Rat TFADELVELS TALEHQEYIT FLEDLKSFVK SQ 
Mouse TFADELVELS TALEHQEYIT FLEDLKSFVK NQ 
Human TFADELVELS TALEHQEYIT FLEDLKSFVK SQ 
Fig. 1. Alignment of the cDNA-derived peptide sequences of rat, 
mouse and human gClqBP. Residues identical in all three species 
are indicated by asterisks. Three potential iV-glycosylation sites are 
underlined. 
Fig. 2. Northern blot analysis of rat and mouse tissue RNA prepa-
rations. Total RNA was isolated from the mouse tissues shown. 
Poly(A)+ RNA was prepared from the male (M) and female (F) rat 
tissues indicated. RNA was separated on formaldehyde-containing 
agarose gels, transferred to nylon membranes and probed with 32P-
labeled RB7.12 cDNA (A). The position of RNA size standards is 
shown left, and the size and position of rRNAs in the total RNA 
preparations is shown right. The Northern blot shown in A was 
subsequently hybridised with a a-32P-labeled (3-actin cDNA probe 
(B). 
Sequencing of the two longest clones revealed extensive ho-
mology with the published human sequence. As these clones 
were incomplete at their 5' ends, they were used to screen a 
rat brain cortex cDNA library, yielding clone RB7.12 (1124 
bp). RB7.12 contains a 5' untranslated region of 45 bp fol-
lowed by an 834 bp open reading frame and a 3' untranslated 
region of 245 bp. A putative polyadenylation initiation signal 
(aataaa) is located 19 bp upstream of the poly(A)+ tail. Anal-
ysis of the three different rat cDNA clones revealed complete 
sequence identity. 
RB7.12 was used to screen a mouse liver cDNA library. 
One clone, MG2 (1127 bp), encompasses the entire coding 
region. Sequencing showed that, like RB7.12, MG2 contains 
an open reading frame of 834 bp. The sequence data are 
available from the EMBL database, under accession numbers 
AJ001102 (rat) and AJ001101 (mouse). 
The cDNA-derived amino acid sequences are compared in 
Fig. 1. Human gClqBP is reported to be synthesised as a pre-
pro protein of 282 residues, of which the first 73 amino acids 
comprise a 13 residue leader peptide followed by a 60 residue 
hydrophobic stretch. The mature protein begins at residue 74, 
a leucine, which we have designated residue 1. Both rodent 
gClqBP pre-pro proteins are 4 residues shorter than the hu-
man sequence. None of the gClqBP proteins contain classical 
transmembrane or GPI anchor domains. 
There is a striking degree of cross-species conservation: rat 
and mouse share a degree of identity of 97.6%, and either of 
the rodent sequences is 89.9% identical to the human amino 
acid sequence. Differences are mostly confined to the N-ter-
minus. The C-terminus contains a region of 60 residues which 
is identical in all three species. 3 potential N-glycosylation 
sites (underlined) are entirely conserved. Total RNA from 
mouse tissues and poly(A)+ selected RNA from rat tissues 
was analysed by Northern blotting. A single gClqBP 
mRNA species of ~1 .3 kbp is abundantly expressed in all 
tissues, except in mouse lung, where a weaker signal was de-
tected (Fig. 2A). Northern blots were normalised using a f$-
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actin cDNA probe (Fig. 2B). Note that while preparations 4 
and 5 (female rat heart and male rat kidney, respectively) 
contain less RNA than the other preparations, the weaker 
signals from rat livers RNAs are consistent with previous 
reports that liver has ~2 .5 times less p-actin mRNA than 
muscular tissues like heart [34]. In other experiments various 
human cell lines - including Raji (B lymphoblastoid), K562 
(erythroblastoid), T47D (breast carcinoma), HT29 (adenocar-
cinoma), TP410 (neuroblastoma), TP379 (glioblastoma) and 
HL60 (promyelocytic leukaemia) - were all shown to express 
a single ~1.3 kbp gClqBP mRNA transcript (data not 
shown). 
To confirm that RB7.12 encodes a Clq-binding protein, 
and to assess the extent of cross-species conservation, we pre-
pared recombinant rat gClqBP thiofusion protein. On West-
ern blots, this fusion protein strongly stained with anti-human 
gClqBP antisera, whereas no staining was observed for the 
thioredoxin fusion-partner alone (data not shown). We next 
devised a solid phase binding assay to determine whether rat 
gClqBP binds to human Clq. A microtitre plate was coated 
with human Clq (1-10 ng/ml) as described in Section 2. As 
shown in Fig. 3, recombinant rat gClqBP thiofusion protein 
binds to human Clq in a saturable, concentration-dependent 
manner, whereas thioredoxin peptide alone shows nominal 
binding. Rat mesangial cells (RMC) were shown to express 
gClqBP mRNA by Northern blot analysis. Western blot 
analyses using polyclonal rabbit antibodies raised against re-
combinant rat gClqBP revealed the presence of gClqBP in 
cell lysates and culture supernatants of cultured RMC (not 
shown). FACS analyses demonstrated that gClqBP is not ex-
pressed on the surface of RMC (Fig. 4A), but is abundantly 
expressed intracellularly as seen after permeabilisation with 
saponin (Fig. 4B). Western blots and ELISA showed that 
gClqBP is present in rat serum at low levels (data not shown). 
2.5 5 7.5 10 
[Human] Clq fig/ml 
Fig. 3. Recombinant rat gClqBP binds to human Clq. A microtitre 
plate was coated with human Clq at the concentrations indicated 
(abscissa). Biotinylated proteins were added and binding assessed as 
described in Section 2. Measurements were carried out in triplicate 
(see error bars). 
1 0 * 
10 M 
Log fluorescence 
Fig. 4. gClqBP is synthesised by RMC, but is not expressed on the 
cell surface. Saponin permeabilised (A) or untreated (B) RMC were 
incubated with either anti-rat gClqBP polyclonal antibodies, pre-im-
mune rabbit serum (negative control) or anti-Thy-1 antibodies (posi-
tive control). The monoclonal mouse anti-rat Thy-1 antibody 
(IgG2a) was raised as previously described [38]. Antibody binding 
was assessed by addition of a FITC conjugated goat anti-rabbit sec-
ondary antibody. 
4. Discussion 
Characterisation of the rat and mouse homologues of 
gClqBP revealed that the primary structure of this molecule 
is highly conserved. Moreover, we have shown that rat 
gClqBP avidly binds to human Clq. The 1.3 kbp gClqBP 
mRNA is abundantly and constitutively expressed in every 
tissue and cell line examined. Some confusion surrounds the 
precise cellular location of gClqBP. In the first report on this 
molecule [16], confocal scanning laser microscopy results in-
dicated that gClqBP is located in the vicinity of the plasma 
membrane in Raji cells. It was therefore suggested that this 
molecule may represent a novel type of cell surface receptor 
for Clq binding to the globular 'heads' of Clq (gClqR) [16]. 
However, van den Berg et al. [37] were unable to detect 
gClqBP on Raji cells using FACS analysis unless the cells 
had first been permeabilised with saponin. Likewise, another 
group reported that gClqR is mainly localised in the vesicular 
fraction, but not on the surface of endothelial cells [38]. We 
have shown that in cultured RMC gClqBP expression is in-
tracellular and gClqBP detectable in the cell culture super-
natant, but absent on the cell surface. Combined, these results 
strongly reinforce the assertion that gClqBP is an intracellular 
protein, and contradict the previous suggestion that it might 
act as a functional cell surface receptor for Clq. We therefore 
favour the term gClqBP rather than gClqR for this Clq 
binding protein. 
The discovery of gClqBP in rat serum, with its proven Clq 
binding capacity and its ability to inhibit Cl activation, sug-
gests a possible complement regulatory role. 
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